Andrew T. Bender

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Andrew T. Bender, A.S. Gardberg, Albertina Pereira et al. · Molecular Pharmacology · 2017 · 188 citations

Life Sciences, Immunology, Pharmacology +17

Neuronal Nitric-oxide Synthase Is Regulated by the hsp90-based Chaperone System in Vivo

Andrew T. Bender, Adam M. Silverstein, Damon R. Demady et al. · Journal of Biological Chemistry · 1999 · 158 citations · Full text

Life Sciences, Biochemistry, Neuroscience +14

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

Philipp Haselmayer, Montserrat Camps, Lesley Liu‐Bujalski et al. · The Journal of Immunology · 2019 · 148 citations · Full text

Medicine, Immunology, Pharmacology +17

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 140 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

TLR7 and TLR8 Differentially Activate the IRF and NF-κB Pathways in Specific Cell Types to Promote Inflammation

Andrew T. Bender, Evgeni P. Tzvetkov, Albertina Pereira et al. · ImmunoHorizons · 2020 · 118 citations · Full text

Life Sciences, Immunology, Molecular Biology +17